The biological foundation of this progress lies in the ERBB2 oncogene, which encodes the HER2 receptor tyrosine kinase. Amplification of ERBB2 drives constitutive signaling through downstream pathways that promote proliferation, survival and invasion, and it was first linked to aggressive breast cancer behavior and shortened survival in landmark work published in Science in 1987. That discovery created the therapeutic target. Monoclonal antibodies such as trastuzumab and pertuzumab, which bind the extracellular domain of the receptor and block signaling and antibody-dependent cellular cytotoxicity, were followed by small-molecule tyrosine-kinase inhibitors that act intracellularly, and most recently by antibody–drug conjugates (ADCs) that couple a HER2-directed antibody to a cytotoxic payload released selectively at the tumor site.

The most consequential recent arrival is trastuzumab deruxtecan (T-DXd), an ADC with a high drug-to-antibody ratio, a cleavable linker and a membrane-permeable payload that exerts a bystander effect on neighboring tumor cells. Originally demonstrated in heavily pretreated metastatic disease, T-DXd has now been moved rapidly into earlier lines of therapy and even into the curative setting. The review highlights its emerging roles in the first-line metastatic setting — where the DESTINY-Breast09 trial showed that T-DXd plus pertuzumab outperformed the traditional taxane, trastuzumab and pertuzumab regimen — as adjuvant treatment for high-risk residual disease after neoadjuvant chemotherapy, and as a neoadjuvant option in high-risk early breast cancer, as tested in DESTINY-Breast11. Each step forward creates new opportunity but also new uncertainty about optimal sequencing, duration and retreatment.

In early-stage disease, right-sizing cuts in two directions. For patients with low-risk tumors — small, node-negative cancers — the field has successfully de-intensified therapy. The APT trial established that weekly paclitaxel plus trastuzumab delivers excellent long-term outcomes for node-negative disease, and the ATEMPT trial compared the ADC trastuzumab emtansine (T-DM1) with that regimen in stage I disease, showing comparable efficacy with a different toxicity profile. Even more minimalist approaches, such as chemotherapy-free dual HER2 blockade in selected patients, are being explored in trials like DECRESCENDO and WSG-ADAPT, supported by biomarkers such as the HER2-enriched intrinsic subtype and tumor-infiltrating lymphocytes that identify tumors most likely to respond to antibody therapy alone.

For patients with stage II–III disease, the focus has shifted to optimizing the neoadjuvant chemotherapy backbone. Anthracyclines, once standard, have been progressively dropped from many HER2-directed regimens after trials such as TRAIN-2 demonstrated comparable outcomes without them, sparing patients cardiac and secondary-leukemia risks. Carboplatin, too, is being re-evaluated: the randomized phase III neoCARHP trial showed noninferiority of taxane-based dual blockade without carboplatin, and the HELEN-006 trial found that weekly nab-paclitaxel with trastuzumab and pertuzumab matched the classic docetaxel–carboplatin doublet. These de-escalation strategies matter because long-term survival in early HER2-positive disease is now so favorable that late toxicities and quality of life weigh heavily in treatment decisions.

At the other end of the early-disease spectrum sits the patient with residual invasive disease after neoadjuvant therapy, historically the group at highest relapse risk. The KATHERINE trial established adjuvant T-DM1 as the standard for these patients, and the more recent DESTINY-Breast05 program has now pushed T-DXd into this space for high-risk residual disease, following evidence from a phase III trial reported in the New England Journal of Medicine that T-DXd improved invasive disease-free survival in this population. The review emphasizes that residual disease is heterogeneous — varying in size, nodal status, hormone receptor status and residual cancer burden — and that escalation should be risk-based rather than uniform, with genomic tools such as HER2DX and circulating tumor DNA assays under development to refine who truly needs intensification.

In metastatic disease, the algorithm is being rebuilt around two concepts: maintenance therapy and first-line intensification. After induction with a taxane plus trastuzumab and pertuzumab, patients traditionally continued dual antibody therapy alone. New maintenance options are expanding that framework. The HER2CLIMB-05 phase III trial tested tucatinib — a highly selective HER2 tyrosine-kinase inhibitor with central nervous system activity — versus placebo added to trastuzumab and pertuzumab as first-line maintenance, while for hormone receptor-positive disease the addition of the CDK4/6 inhibitor palbociclib to trastuzumab and endocrine therapy has shown benefit in advanced settings. Meanwhile, DESTINY-Breast09 has positioned continuous T-DXd plus pertuzumab as a new first-line standard, raising unresolved questions about how long such intensive therapy should continue, how to sequence subsequent lines, and whether patients with exceptional responses might eventually de-escalate.

Biomarkers are emerging as the connective tissue that could make right-sizing practical at scale. Quantitative HER2 expression measured by tissue and plasma profiling correlates with ADC activity and may predict benefit from T-DXd. The PAM50 intrinsic subtype, particularly the HER2-enriched phenotype, predicts pathological complete response to HER2-directed therapy and underpins the commercially available HER2DX genomic assay, which is now being tested prospectively in the DEFINITIVE trial. Dynamic imaging biomarkers, including FDG-PET response adapted in the PHERGain strategy, allow chemotherapy de-escalation in patients showing early metabolic response, and ultrasensitive circulating tumor DNA tracking can identify minimal residual disease and exceptional responders, informing trials such as HEROES that explore treatment withdrawal in patients with sustained deep response.

The review also confronts persistent evidence gaps and equity concerns. The optimal duration of first-line T-DXd plus pertuzumab remains unknown, as does the value of retreating with T-DXd after prior exposure, an approach being studied in the EN-SEMBLE cohort. Brain metastases remain a dominant site of failure in HER2-positive disease, and the review details how tucatinib-based regimens, T-DXd and modern stereotactic radiation strategies are reshaping central nervous system management, while noting the risk of symptomatic necrosis when ADCs are combined with brain radiotherapy. Globally, access to HER2-targeted therapies remains uneven, and real-world data reveal racial and ethnic disparities in outcomes even among patients receiving ADCs, underscoring that right-sizing must include right of access.

What emerges from this synthesis is a vision of HER2-positive breast cancer care as a continuum of calibrated decisions rather than a fixed sequence of regimens. For the low-risk patient, the goal is a cure with the least toxicity; for the high-risk residual-disease patient, intelligent escalation; for the metastatic patient, durable control with the flexibility to intensify, maintain or step down as biology dictates. The tools — ADCs, kinase inhibitors, CDK4/6 inhibitors, genomic classifiers, ctDNA and molecular imaging — are largely in hand. The task now, the authors conclude, is to deploy them with precision, powered by prospective biomarker-driven trials that convert an era of drug abundance into an era of individually right-sized cures.

Subject of Research: Risk-adapted treatment strategies for HER2-positive breast cancer across early-stage and metastatic settings

Article Title: Right-sizing treatment for HER2-positive breast cancer: evolving algorithms across the disease continuum

Article References: Tarantino, P., Valenza, C., Segui, E., Lin, N. U., Prat, A., Curigliano, G., Waks, A. G., & Tolaney, S. M. (2026). Right-sizing treatment for HER2-positive breast cancer: evolving algorithms across the disease continuum. Nature Reviews Clinical Oncology. https://doi.org/10.1038/s41571-026-01211-5

Image Credits: AI Generated

DOI: 10.1038/s41571-026-01211-5

Keywords: HER2-positive breast cancer, trastuzumab deruxtecan, antibody-drug conjugates, de-escalation, neoadjuvant therapy, residual disease, maintenance therapy, tucatinib, palbociclib, circulating tumor DNA, HER2DX, biomarkers

The trial, known formally as EA1181, enrolled 2,175 patients with stage II to IIIA HER2-positive breast cancer, a disease stage in which the tumor has grown beyond its site of origin or spread to nearby lymph nodes but remains potentially curable. Instead of the conventional multi-drug chemotherapy backbone, participants received twelve weeks of a regimen abbreviated THP: a single chemotherapy drug, a taxane, combined with two HER2-targeted monoclonal antibodies, trastuzumab and pertuzumab. This dual-antibody strategy attacks the HER2 receptor from two angles, blocking signaling through the receptor itself and recruiting immune mechanisms to destroy tumor cells that display the protein. The chemotherapy component, meanwhile, is deliberately pared down to one agent rather than the anthracycline- and taxane-based combinations that have historically defined neoadjuvant treatment, sparing patients the cardiac toxicity, secondary leukemia risk, and cumulative side effects associated with more aggressive protocols.

The yardstick by which the trial measured success is pathologic complete response, or pCR, a term that carries enormous weight in breast cancer research. A pCR means that when surgeons remove the breast tissue and regional lymph nodes after preoperative therapy, pathologists find no remaining invasive cancer. It is the strongest early signal available that a patient’s tumor has been eradicated, and it has been validated across large datasets as a predictor of long-term recurrence-free and overall survival. In CompassHER2-pCR, patients who achieved a pCR after their twelve weeks of THP received no further chemotherapy at all. They simply continued the dual HER2 blockade with trastuzumab and pertuzumab to complete a full year of targeted therapy, avoiding any additional cytotoxic drugs. Among the 2,141 patients who actually began treatment, 43.8 percent reached this benchmark, a striking figure given how little chemotherapy they had received.

Beneath that headline number lies a far more clinically useful story, because the response rates varied dramatically depending on the biology of each patient’s tumor. Among women whose cancers were estrogen receptor-negative, meaning the tumor does not rely on the hormone estrogen to grow, the pCR rate climbed to 63.7 percent. In contrast, patients with estrogen receptor-positive disease, which tends to be more indolent and less sensitive to chemotherapy, achieved a pCR rate of 32.4 percent. The secondary analyses published in the Journal of Clinical Oncology went further, identifying a cluster of tumor characteristics associated with a greater likelihood of complete response: estrogen receptor-negative status or low expression of the estrogen receptor, absent or low progesterone receptor expression, tumors classified as HER2 IHC 3+, the strongest level of HER2 protein staining on diagnostic testing, and treatment with weekly paclitaxel rather than an alternative taxane schedule. Each of these variables, individually and in combination, helps refine the probability that a given patient will respond to the abbreviated regimen.

Lead investigator Nadine M. Tung, a medical oncologist at Beth Israel Deaconess Medical Center in Boston, framed the trial’s philosophy in terms of precision rather than deprivation. The goal, she emphasized, is not simply to give patients less treatment, but to determine whether each patient can receive the treatment needed to achieve the best possible outcome while avoiding chemotherapy that may not be necessary. She noted that the recurrence-free survival results will be critical to that determination, a point that underscores the central tension in de-escalation research: a high pCR rate is encouraging, but the field ultimately needs proof that patients spared additional chemotherapy do not pay for it with higher relapse rates. To that end, the trial continues to follow patients who achieved a pCR, with three-year recurrence-free survival serving as the study’s primary endpoint.

The molecular dimension of the analysis adds a layer of sophistication that reflects where the field is heading. Researchers evaluated HER2DX, a genomic assay developed specifically for HER2-positive breast cancer, which measures the activity of a panel of genes related to HER2 signaling, immune response, cell proliferation, and estrogen receptor biology to produce a score predicting the likelihood of pCR. Diagnostic tumor samples from a representative subset of 569 trial participants were shipped for central analysis using the validated and standardized test, and crucially, the laboratory performed the testing while blinded to all clinical outcomes, eliminating any risk of bias in the interpretation. The results were unambiguous. Among patients with high HER2DX pCR scores, 68 percent achieved a pathologic complete response, compared with just 19 percent of those with low scores, a gap of 49 percentage points.

What makes the HER2DX findings particularly compelling is that the test’s predictive power held up within both hormone receptor subgroups. In ER-positive disease, the pCR rate was 58 percent among high scorers versus 18 percent among low scorers; in ER-negative disease, it was 70 percent versus 31 percent. In both settings the difference between high and low scores exceeded 30 percentage points, suggesting that the genomic signal captures biologic information that the standard clinical markers do not fully encode. Perhaps most importantly from a methodological standpoint, the high HER2DX pCR score remained independently associated with pathologic complete response after statistical adjustment for clinical and pathologic factors and for the type of taxane the patient received. In other words, the molecular test added genuine predictive information on top of what clinicians could already glean from hormone receptor status, HER2 staining intensity, and treatment details.

Tung suggested that the two strands of evidence, the clinical characteristics and the molecular biomarkers, are most powerful when woven together. Combining information routinely available about a patient’s tumor with molecular biomarker data, she noted, may improve the ability to identify the patients most likely to achieve a complete response with a less intensive chemotherapy approach. She was careful, however, to add a caveat that reflects scientific discipline rather than commercial enthusiasm: further research is needed to determine how these factors should actually be used to guide treatment decisions. That distinction matters, because a biomarker that predicts response is not the same as a validated tool for withholding therapy, and the field has seen promising predictors fail to change practice when survival outcomes did not follow.

Scale and design give CompassHER2-pCR unusual authority in this debate. It is the largest prospective trial of twelve-week neoadjuvant THP ever conducted in stage II to IIIA HER2-positive breast cancer, and it is also the only trial in this setting that is statistically powered to evaluate survival outcomes rather than response rates alone. That combination positions the study to answer the question that matters most to patients and their physicians: whether the substantial proportion of patients who achieve a pCR with abbreviated therapy can be confidently spared further chemotherapy without compromising their long-term cure. The trial sits within the broader CompassHER2 program, a collaboration between ECOG-ACRIN and the Alliance for Clinical Trials in Oncology, both cooperative groups within the National Cancer Institute’s National Clinical Trials Network, with additional support from the Breast Cancer Research Foundation and Susan G. Komen.

For patients, the practical message of the new analyses is one of cautious optimism. A substantial fraction of people with early-stage HER2-positive breast cancer, particularly those with HER2-positive, ER-negative tumors and favorable molecular profiles, can achieve a complete pathologic response after only twelve weeks of a single chemotherapy drug paired with dual HER2 blockade, potentially avoiding months of more toxic treatment. For oncologists, the results supply a graded risk framework: hormone receptor status, progesterone receptor expression, HER2 staining intensity, taxane schedule, and now a validated genomic score can be combined to estimate each patient’s probability of response before the first dose is given. The pending three-year recurrence-free survival data will determine whether that framework becomes standard practice, but the direction of travel in HER2-positive breast cancer is clear. After two decades of escalating treatment intensity, the field is now engineering its retreat with the same rigor it once applied to its advance, and CompassHER2-pCR is providing the evidence base for that carefully measured step backward.

Subject of Research: Predictors of pathologic complete response to 12-week neoadjuvant THP therapy in stage II-IIIA HER2-positive breast cancer

Article Title: Major HER2+ breast cancer trial identifies factors associated with pathologic complete response to less intensive chemotherapy

Article References: Major HER2+ breast cancer trial identifies factors associated with pathologic complete response to less intensive chemotherapy. (n.d.). Original publication

Image Credits: AI Generated

DOI: Not provided

Keywords: HER2-positive breast cancer, CompassHER2-pCR, pathologic complete response, neoadjuvant therapy, trastuzumab, pertuzumab, paclitaxel, HER2DX, ECOG-ACRIN, chemotherapy de-escalation, biomarkers, Journal of Clinical Oncology